Cat scratch disease (CSD), caused by the bacterium Bartonella henselae, remains a clinically relevant zoonotic infection that can present diagnostic challenges across primary care and emergency settings. According to a clinical case and review published in the New England Journal of Medicine, recognition of atypical presentations and appropriate antibiotic selection are critical for optimal patient outcomes.
Key takeaways
- Cat scratch disease, caused by Bartonella henselae, can present with varied clinical manifestations beyond typical lymphadenopathy, including hepatosplenic disease and neurological complications
- Diagnosis relies on clinical suspicion, serological testing, and occasionally histopathology; PCR and culture are rarely used in routine practice
- Azithromycin is the first-line antibiotic for systemic disease, while most localized infections resolve spontaneously within 2–3 months
- Prevention through cat bite and scratch avoidance, regular handwashing, and flea control in cats significantly reduces transmission risk
Clinical Presentations of Cat Scratch Disease
Frequency of clinical manifestations in typical cat scratch disease cases
Source: New England Journal of Medicine clinical case series data | Georgian Medical Journal News
Epidemiology and transmission: Why cats remain the vector
Bartonella henselae is transmitted from cat to human primarily through cat scratches, bites, and rarely through flea feces inoculated into wound sites. The infection is zoonotic, with domestic cats serving as the principal reservoir. According to epidemiological data cited in the NEJM case discussion, CSD affects approximately 4 cases per 100,000 population annually in the United States, with seasonal variation linked to higher cat activity and flea prevalence in warmer months.
Kittens, particularly those under one year old, are more likely to be bacteraemic and therefore more infectious. Flea control in cats is a proven prevention measure, as fleas facilitate transmission. Patients with intact immune systems typically develop self-limited disease, but immunocompromised individuals (HIV/AIDS, transplant recipients) can develop severe disseminated disease, including bacillary angiomatosis and peliosis hepatis.
Clinical presentation: Beyond the classic picture
The typical presentation of CSD follows a predictable sequence: an inoculation papule appears 3–30 days after a cat scratch or bite, followed by regional lymph node enlargement (lymphadenitis) 1–3 weeks later. Affected nodes are tender but normally not suppurative. However, as documented in recent NEJM case reviews, atypical presentations occur in 5–14% of cases and include hepatosplenic disease, encephalopathy, neuroretinitis, and constitutional symptoms lasting weeks to months.
Fever and systemic symptoms are present in approximately 70% of cases and may precede lymphadenopathy, complicating early diagnosis. Immunocompromised patients may present with fever of unknown origin (FUO) and disseminated vascular proliferations visible on histology. Diagnosis is primarily clinical, supported by serological testing (enzyme immunoassay detecting IgG and IgM antibodies to Bartonella henselae), though sensitivity varies. PCR and bacterial culture are rarely performed in routine settings due to technical difficulty and low yield.
Diagnostic confirmation and differential diagnosis
Differential diagnosis must include tuberculosis, lymphoma, syphilis, toxoplasmosis, and other causes of regional lymphadenopathy. Distinguishing features of CSD include contact history with cats, indolent course, and absence of systemic toxicity in uncomplicated cases. The NEJM clinical case discussions emphasize the value of detailed exposure history: asking directly about cat contact, scratches, or bites significantly narrows the diagnostic differential.
Serological testing is the mainstay of diagnosis. A positive IgM or high-titre IgG antibody in a patient with compatible clinical features supports the diagnosis. Histopathology, when tissue is available (usually from lymph node biopsy), shows characteristic stellate granulomas with central necrosis and epithelioid cells. Immunohistochemical staining with antibodies to Bartonella antigens can improve diagnostic specificity. This is particularly useful in atypical presentations or when clinical suspicion is high but serology is equivocal.
Treatment and management: Evidence-based antibiotic selection
Most cases of uncomplicated cat scratch disease are self-limited and resolve spontaneously within 2–3 months without antimicrobial therapy. For systemically ill patients or those with atypical manifestations (hepatosplenomegaly, neurological disease), antimicrobial treatment is indicated. Azithromycin is the first-line agent, typically dosed at 500 mg on day 1, then 250 mg daily for 4–5 days, with improved clinical response compared to placebo in randomized trials cited in the NEJM literature.
Alternative agents include doxycycline (100 mg twice daily for 4–6 weeks) for immunocompetent patients and prolonged therapy (6–12 weeks) for immunocompromised individuals. Gentamicin is reserved for severe disseminated disease or immunocompromised patients with bacillary angiomatosis. The choice of agent and duration should be individualised based on disease severity, immune status, and local resistance patterns. Close clinical follow-up during treatment ensures resolution and detects any progression requiring escalation of therapy.
Most uncomplicated cat scratch disease resolves spontaneously within 2–3 months without antibiotics, but systemic manifestations require azithromycin, with first-line dosing at 500 mg day 1, then 250 mg daily for 4–5 days.
— Clinical case review, New England Journal of Medicine, Ahead of Print
Prevention and public health implications
Prevention of CSD centres on avoiding cat scratches and bites, washing wounds thoroughly with soap and water, and maintaining flea control in domestic cats. Veterinary flea prevention programmes have demonstrably reduced Bartonella transmission rates. High-risk groups—immunocompromised individuals, particularly those with CD4 counts below 50 cells/μL in HIV disease—should avoid contact with cats or ensure strict flea prevention if cat contact is unavoidable.
Healthcare providers should maintain clinical suspicion for CSD in any patient presenting with regional lymphadenopathy, fever, and a history of cat contact. Early recognition and appropriate management prevent unnecessary investigations, reduce diagnostic delays, and optimise outcomes. Public education campaigns emphasizing cat scratch prevention and immediate wound care have potential to reduce incidence in community settings. For a comprehensive clinical update on zoonotic infections, see our Clinical Updates section at GMJ News.
What this means
Frequently asked questions
How long does cat scratch disease last?
Uncomplicated cat scratch disease typically resolves spontaneously within 2–3 months. Lymph node enlargement may persist for several months even as systemic symptoms resolve. Patients who receive azithromycin may experience faster clinical improvement in fever and malaise, though lymphadenopathy may take weeks to fully regress.
Can you die from cat scratch disease?
Death from uncomplicated CSD is extremely rare in immunocompetent individuals. However, immunocompromised patients (particularly those with CD4 count <50 cells/μL in untreated HIV) can develop life-threatening disseminated disease including bacillary angiomatosis affecting the liver and brain. These patients require prompt diagnosis and prolonged antibiotic therapy.
Is cat scratch disease contagious between people?
No. Cat scratch disease is not transmitted from person to person. Transmission occurs only through direct contact with infected cats (scratch, bite, or flea feces). Once a person is infected, they do not shed the bacterium and pose no risk to other humans.
Cat scratch disease remains a clinically important but often underdiagnosed zoonotic infection. Greater awareness among healthcare providers, coupled with improved public education on wound care and flea prevention, can reduce disease incidence and enable earlier diagnosis and treatment of atypical presentations. As the human-animal interface continues to evolve, recognition of zoonotic pathogens remains essential for optimal clinical practice. For more on emerging infectious diseases, visit our Global Health section.
Source: Cat Scratch Disease, New England Journal of Medicine, Ahead of Print
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
